This morning, during my daily Bible study, I encountered a profound reflection on transformation:
Transformation is a massive change. It’s thorough. Complete. A total difference. Like a caterpillar becoming a butterfly, transformation brings an end to the old and a beginning to the new.
These words prompted a moment of introspection. In the business landscape (particularly within sectors like technology, healthcare, and innovation) we frequently invoke the term “transformation.” Yet, one must question whether this invocation truly reflects substantive evolution or merely serves as aspirational language.
Consider the domain of clinical trials, where the imperative for genuine transformation is most acute. A friend, Maya Zlatanova, CEO and Co-Founder of FindMeCure and TrialHub, recently shared an insightful post on LinkedIn following her 15 years of experience in clinical research. At the #Dpharm2025 conference, she articulated a persistent frustration: the recurrence of unchanging metrics that underscore systemic inefficiencies. As she poignantly asked:
Aren’t we sick and tired from seeing same numbers and not moving the needle towards better statistics? What is the number 1 thing you think we should do to change any of these numbers?
The metrics she references are all too familiar:
- 80-85% of trials fail to meet enrollment targets.
- Protocols undergo an average of 50+ amendments.
- Patient dropout rates range from 20-30%.
- Timelines extend 20-30% beyond projections.
The ensuing discussion in the comments revealed a chorus of informed perspectives. Sophie Wintrich advocated for patient co-creation in trial design, a recommendation echoed by regulatory bodies and the World Health Organization, emphasizing human-centered approaches over automated alternatives. Adrian Wright proposed a moratorium on presentations that merely reiterate these statistics without demonstrating measurable improvements. Niina Laaksonen raised a valid concern about the provenance of the 80-85% enrollment failure figure, suggesting it may represent an amplified industry heuristic rather than a rigorously sourced datum. Duncan R. Shaw highlighted the structural barrier: entrenched financial incentives that prioritize status quo over innovation.This dialogue is not mere commentary; it signals a critical juncture. Clinical trials represent the vanguard of scientific advancement, ostensibly transforming nascent discoveries into therapies that extend and enhance lives. They demand an unequivocal end to antiquated practices and the emergence of a streamlined, equitable paradigm. Regrettably, progress remains incremental at best.
Bridging the Divide: From Stagnation to Sustainable Progress
Several interconnected factors contribute to this inertia:
- Protocol Design Deficiencies: As Lorraine Dishman observed, these metrics are symptomatic of upstream decisions. Trials often diverge from the practical realities faced by patients and sites, leading to cascading delays. Authentic transformation begins with integrating patient insights at the protocol development stage, fostering designs that are feasible and patient-aligned from inception.
- Technological Fragmentation: In my response to Doug Bain’s comment on the post, I expressed strong alignment with his emphasis on a unified platform. Such a system mitigates trial complexity by establishing a single source of truth, enabling real-time decision-making, such as daily recruitment strategy adjustments rather than periodic reviews. It also streamlines regulatory compliance (e.g., USDM enablement) and facilitates protocol finalization on the first iteration, easing burdens on sites, contract research organizations (CROs), and sponsors while enhancing performance aggregation across studies.
- Cultural Resistance to Innovation: Samuel Pavin astutely noted that complexity is navigable through evolved processes and tools that embrace novel solutions. Technologies like AI-driven patient matching and blockchain for data integrity hold promise for simplifying recruitment, yet adoption is hindered by institutional caution. Overcoming this requires cultivating trust and a willingness to retire legacy apprehensions.
- Incentive Misalignment: Duncan Shaw’s observation resonates deeply: without reorienting the economic framework to reward outcomes (such as shared savings from accelerated enrollment), meaningful reform will remain elusive.
What Would Real Transformation Look Like?
In my years engaging with industry leaders, customers, and innovators, one phrase consistently lights up the room: “Imagine a world where clinical trials ran like Amazon.”
There’s no mystery to it: most people instantly conjure a vivid picture of seamless efficiency, intuitive experiences, and relentless optimization. It’s the gold standard for what transformation feels like: frictionless, customer-obsessed, and powered by data that anticipates needs before they’re even voiced.
Picture that in clinical trials. Patients aren’t buried in endless forms or chasing eligibility rabbit holes; instead, a unified platform surfaces personalized trial matches via a simple app, much like Amazon’s recommendation engine suggests books based on your reading history, except here, it’s life-changing therapies tailored to your medical profile, with one-click consent and real-time updates.
Enrollment? It hits 90%+ targets because recruitment isn’t a quarterly spreadsheet scramble but a dynamic, AI-augmented dashboard that pivots daily, flagging high-potential sites and underperformers like Amazon’s supply chain reroutes packages around delays.
Protocols lock in on the first go, co-designed with patient input from day one, slashing those 50+ amendments because feedback loops are baked in, just as Amazon iterates product listings based on reviews.
Dropouts? They plummet to single digits as the journey mirrors the ease of a Prime delivery: transparent tracking, gentle reminders, and adaptive scheduling that fits around real lives, not rigid calendars.
Timelines? They compress by 30% or more, with clean data flowing into a single source of truth, enabling predictive analytics to preempt bottlenecks before they snag the process. Sites and sponsors collaborate effortlessly, performance metrics aggregated in real time like Amazon’s seller dashboards, rewarding top performers with incentives that align everyone toward outcomes, not billable hours.And the cultural shift?
No more echo-chamber slides at conferences; every pitch proves impact (“We cut delays by 40% with patient-led tweaks”), fostering trust in novel tools that simplify complexity without the fear. Legacy systems fade, replaced by pilots greenlit by the FDA and EMA, all under a financial model that shares the windfall from faster, fairer trials. It’s not utopia; it’s achievable evolution: the caterpillar fully dissolved, wings unfurling in a system that’s as equitable and exhilarating as two-day shipping for hope.
These shifts are attainable, but they hinge on that one decisive act Maya challenged us with: ditching the echo chamber of problem-stating for the hard work of solution-building.
Invest in pilots, scale what works, and measure every step. As with the butterfly’s emergence, true renewal isn’t gentle. It’s a radical reconfiguration. But oh, the freedom on the other side.
What is your foremost recommendation for catalyzing change in clinical trials, or analogous fields? Have you witnessed a pivotal “transformation” in your professional sphere?
I welcome your insights in the comments to collectively advance this dialogue.
#ClinicalTrials #DigitalTransformation #PatientCentricity #Dpharm2025 #HealthInnovation
(This article was inspired by Maya Zlatanova’s reflections and the exhortation in Romans 12:2: “Be transformed by the renewing of your mind.”)
About the author
Bo Lora has witnessed the Internet’s evolution from its early days and now bring that transformative lens to healthcare and life sciences. Just as connected systems revolutionized industries, Bo sees untapped potential in seamless health data flow across the care continuum.
At AWS, he is dedicated to eliminating data silos and making knowledge the engine of next-generation healthcare. He bridges emerging technologies with real-world challenges, uniting partners, customers, and innovators to deliver solutions that save lives. His expertise lies in empowering others: guiding startups through healthcare complexities, linking health systems to cutting-edge tech, and aligning stakeholders around shared goals.
True impact comes from diverse perspectives united by purpose.